Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year gross profit growth rate
Latest
0.00%
↓ 100% vs avg
Percentile
P49
Within normal range
Average
1116.08%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | -100.00% |
| Q4 2024 | -89.10% |
| Q3 2024 | 380.76% |
| Q2 2024 | -528.75% |
| Q1 2024 | -89.90% |
| Q4 2023 | 19900.00% |
| Q3 2023 | 93.85% |
| Q2 2023 | 98.56% |
| Q1 2023 | -1733.33% |
| Q4 2022 | -98.09% |
| Q3 2022 | 2800.56% |
| Q2 2022 | -217.88% |
| Q1 2022 | 105.30% |
| Q4 2021 | -2032.35% |
| Q3 2021 | 106.69% |
| Q2 2021 | -1767.42% |
| Q1 2021 | 104.34% |
| Q4 2020 | -981.43% |
| Q3 2020 | -17.94% |
| Q2 2020 | -53.13% |
| Q1 2020 | 154.68% |
| Q4 2019 | -217.66% |
| Q3 2019 | 238.84% |
| Q2 2019 | -64.40% |
| Q1 2019 | 19.28% |
| Q4 2018 | 201.37% |
| Q3 2018 | -71.34% |
| Q2 2018 | -7.10% |
| Q1 2018 | 100.60% |
| Q4 2017 | -2582.82% |
| Q3 2017 | 31011.10% |
| Q2 2017 | 39.91% |
| Q1 2017 | 44.62% |
| Q4 2016 | 93.66% |
| Q3 2016 | -181.82% |
| Q2 2016 | 24.39% |
| Q1 2016 | -40.65% |